Get the Stockscreener App
2.31
8.70%
-0.22
After Hours:
2.34
0.03
+1.30%
Allogene Therapeutics Inc stock is traded at $2.31, with a volume of 4.71M.
It is down -8.70% in the last 24 hours and up +41.72% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$2.53
Open:
$2.48
24h Volume:
4.71M
Relative Volume:
0.99
Market Cap:
$519.13M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-1.0896
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-15.38%
1M Performance:
+41.72%
6M Performance:
+100.87%
1Y Performance:
+19.69%
1-Day Range:
$2.285
$2.50
1-Week Range:
$2.285
$2.80
52-Week Range:
$0.8621
$2.80
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.31 | 568.57M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance
ALLO: Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact - TradingView
Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares - Stock Titan
Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients - Traders Union
Cancer CAR T firm Allogene sets March 12 call on 2025 results - Stock Titan
Ideas Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
ALLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year HighHere's What Happened - MarketBeat
FOMO Trade: Is Allogene Therapeutics Inc.’s ROE strong enoughGold Moves & Weekly Breakout Watchlists - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%Should You Buy? - MarketBeat
Allogene Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen - MarketBeat
Treasury Yields: Whats the fair value of Blend Labs Inc stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Allogene Therapeutics Faces Financial Challenges Despite Industry Moves - StocksToTrade
Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission - Yahoo Finance
MSN Money - MSN
ALLO: ALPHA-3 aims for a 25%-30% MRD clearance improvement in lymphoma, with pivotal data due in April - TradingView
Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities - Stock Titan
Allogene Therapeutics unveils plans for Virtual Oncology Summit - Traders Union
Atomera Among 3 Promising Penny Stocks - simplywall.st
Will Allogene Therapeutics Inc. stock outperform value stocks2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat
Will Allogene Therapeutics Inc. benefit from geopolitical trendsQuarterly Portfolio Report & Fast Entry Momentum Alerts - mfd.ru
ALLO PE Ratio & Valuation, Is ALLO Overvalued - Intellectia AI
Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic - Barchart.com
Aug Selloffs: Is Bank of Montreal on track to beat earningsPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Dr. Chang (NASDAQ: ALLO) discloses 5.2% Allogene ownership stake - Stock Titan
Will Allogene Therapeutics Inc. outperform small cap indexesEarnings Trend Report & AI Powered Trade Plan Recommendations - mfd.ru
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance
Why Allogene Therapeutics Inc. stock could see breakout soonTreasury Yields & Stock Portfolio Risk Management - mfd.ru
Aug Drivers: Will Allogene Therapeutics Inc stock hit new highs in YEAREarnings Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Allogene Therapeutics Approaches a Defining Period for Its Platform - AD HOC NEWS
Don't Ignore The Insider Selling In Allogene Therapeutics - 富途牛牛
Allogene Therapeutics explores cell therapy trial at ASTCT meeting - Traders Union
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Allogene EVP Roberts sells $63,189 in stock, gains options By Investing.com - Investing.com Canada
Allogene Therapeutics CEO Chang David D sells $171k in stock - Investing.com Canada
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN
Allogene Therapeutics SVP sells $13k in stock By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CEO David Chang Sells 95,269 Shares - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,549 Shares of Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CFO Sells $42,241.76 in Stock - MarketBeat
Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress - Yahoo Finance
Allogene Therapeutics SVP sells $13k in stock - Investing.com Nigeria
Allogene Therapeutics SVP sells $40k in stock By Investing.com - Investing.com Canada
Allogene Therapeutics SVP sells $40k in stock - Investing.com
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):